Recent Updates
Recently added Catalysts
PLRX

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following conferences in March.
Cowen 42nd Annual Health Care Conference: Dr. Coulie will participate in the Respiratory/ Infections panel on Tuesday, March 8, at 2:10 p.m. ET / 11:10 a.m. PT
Oppenheimer 32nd Annual Healthcare Conference: Dr. Coulie will present a company update on Wednesday, March 16, at 3:20 p.m. ET / 12:20 p.m. PT
Interested parties can access these presentations from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time they are made available.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Last updated: Feb 24, 2022